Publications
Body Mass Index Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC
Haplotype Analysis of the T-Cell Receptor Beta (TCRB) Locus by Long-amplicon TCRB Repertoire Sequencing
Oncologist uptake of comprehensive genomic profile guided targeted therapy
Cell proliferation as a biomarker for response to immune checkpoint inhibitors in PD-L1 negative renal cell carcinoma
Cell proliferation as a biomarker for response to immune checkpoint inhibitors in highly inflamed renal cell carcinoma (RCC)
Tumor Mutational Burden (TMB): Assessment of Inter-and Intra-tumor heterogeneity
RNA-sequencing reveals immunotherapy targets in gynecological cancer
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing
Identification of targets for prostate cancer immunotherapy
RNA-Expression Profiling Reveals Immunotherapy Targets in Sarcoma
Tumor mutational burden (TMB) ring study: Comparison of multiple targeted next-generation sequencing (NGS) platforms
Identifying major immune subsets of GI tumors for clinical purposes
Development of a next-generation sequencing-based microsatellite instability assay (MSI NGS) for solid tumor testing
Cell Proliferation Defines an Additional Mechanism of Immune Escape in Non-Small Cell Lung Cancer
PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
Combination immunotherapy selection for non-PD-1 axis driven tumors
Combination immunotherapy selection for PD-1 axis driven tumors
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Chemokine expression signatures in infiltrated vs non-infiltrated tumors
PD-L1 driven excluded phenotype in melanoma
Predicting Response: PD-L1 Biomarker Testing by IHC and RNA-seq
CTLA-4 Overexpression Does Not Confer Response to Ipilimumab in Melanoma
Lung Cancer Mutational Profile Correlates with Immune Profile
Immune Deserts: Low CD8 Gene Expression Correlates with Non-response to Checkpoint Inhibition
Comprehensive Immune and Mutational Profile of Melanoma
Overexpression of Immunotherapeutic Targets in the Immune Desert Phenotype
Comprehensive Characterization of Solid Tumor Immune Profiles for Precision Immunotherapy Using Immune Report Card℠
The Immune-Excluded Phenotype Beyond Colorectal Cancer
Secondary Immunotherapeutic Targets In Inflamed Tumors
Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors
Algorithmic Prediction of Response to Checkpoint Inhibitors
The Inflamed Phenotype in PD-L1 Negative Melanoma and Response to Checkpoint Inhibitors
The Inflamed Phenotype in PD-L1 Negative NSCLC and Response to Checkpoint Inhibitors
Technical variability in NGS immune gene expression and mutation profiling has a nominal effect on tumor classification
NGS reveals specimen characteristics have minimal impact on immune gene expression signature
Tumor microenvironment heterogeneity is not identified across multiple histologically similar tumors from the same patient
Analytical Validation of an Immune Response Assay for Classifying Solid Tumors
Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing
An Algorithmic Approach to Cancer Immune Profiling